Evidence map›Paper›PMID 41356856›Full record

ArticleCureus2025

Rapidly Progressive Dementia: Predictive Clues and a Proposed Diagnostic Approach Focused on Neurodegenerative Causes.

Francisco Gortari, Maria T Rosero, Conrado J Simison, Laura Ottone, Raul C Rey, Mayra Aldecoa, Carlos S Claverie, Guido Dorman

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francisco GortariNeurology, Jose María (JM) Ramos Mejia Hospital, Buenos Aires, ARG.
Maria T RoseroNeurology, Jose María (JM) Ramos Mejia Hospital, Buenos Aires, ARG.
Conrado J SimisonNeurology, Jose María (JM) Ramos Mejia Hospital, Buenos Aires, ARG.
Laura OttoneNeurology, Jose María (JM) Ramos Mejia Hospital, Buenos Aires, ARG.
Raul C ReyNeurology, Jose María (JM) Ramos Mejia Hospital, Buenos Aires, ARG.
Mayra AldecoaNeurology, Jose María (JM) Ramos Mejia Hospital, Buenos Aires, ARG.
Carlos S ClaverieStroke Center, Favaloro Foundation, Buenos Aires, ARG.
Guido DormanNeurology, Jose María (JM) Ramos Mejia Hospital, Buenos Aires, ARG.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Rapidly progressive dementia (RPD) is a clinical challenge due to the relatively high prevalence of potentially reversible causes, some of which have specific treatments. Consequently, the diagnostic approach is broader than in slowly progressive dementias. Nevertheless, neurodegenerative (ND) diseases remain a leading etiology in most RPD cohorts. Underreporting of prior cognitive decline contributes to extensive testing, higher costs, longer diagnostic timelines, and invasive procedures, often without identifying causes beyond ND pathology. Objective This study aims to evaluate the predictive utility of factors such as age of onset, symptom duration, absence of neurological signs, and absence of crisis for identifying ND etiologies in patients with RPD. Therefore, we aim to identify a subgroup of patients for whom the diagnostic and therapeutic approach could be optimized, facilitating an accurate diagnosis and improving the prognosis and treatment of these cases. Materials and methods A retrospective, observational, cross-sectional study was conducted of 135 diagnoses, with RPD patients treated at a public hospital in Buenos Aires (2013-2024). Data included demographics, comorbidities, clinical features, diagnostic delay, laboratory and imaging findings, final diagnosis, follow-up, and outcomes. Quantitative data were summarized using means or medians, while categorical data were expressed as percentages. R and RStudio software (version 4.3.2, October 31, 2023) (Posit Software, Boston, MA, US) were used for variable analysis. Results A comprehensive analysis was performed on 135 patients diagnosed with RPD, aiming to develop an algorithm to identify ND diseases as the underlying etiology. Of these, 30 patients were excluded after the initial diagnostic evaluation revealed a definite cause. Among the remaining 105 patients, an additional 35 were excluded because imaging findings suggested a non-ND etiology (such as temporal, thalamic, insular, frontal, and cortical hyperintensities on diffusion-weighted imaging (DWI), T2, and fluid-attenuated inversion recovery (FLAIR) or contrast enhancement). In the remaining 70 patients, the predictive value of selected variables, such as age, symptom duration, absence of neurological signs, and crisis, was evaluated. Among these, age and symptom duration showed significant predictive value for ND etiology (sensitivity (Se) 55%, specificity (Sp) 75%, positive predictive value (PPV) 72%, negative predictive value (NPV) 58%; p = 0.02). Logistic regression, including age, disease progression, and absence of neurological signs, identified age as an independent predictor (p = 0.004). Model performance was moderate (area under the curve (AUC) 0.74; 95% confidence interval (CI) 0.63-0.86). Finally, when applying the model to the cohort, 11 patients were identified, all with ND etiology. Conclusion Considering these factors, ND disorders-historically viewed as diagnoses of exclusion-may become a central component of the diagnostic approach to RPD, alongside autoimmune encephalitis (AE). We propose the development of an algorithm based on a predictive model that allows for the identification of a subgroup of patients in whom the diagnostic approach can be optimized, avoiding unnecessary studies and prioritizing the early identification of a possible ND etiology.

Indexed as

aducanumablecanemabneurodegenerative diseasespredictive scorerapidly progressive dementiatau biomarkers

Identifiers

PMID41356856
PMCPMC12678211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.